An integrative network inference approach to predict mechanisms of cancer chemoresistance.
暂无分享,去创建一个
[1] R. Hyde,et al. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). , 2001, Molecular membrane biology.
[2] V. Anne Smith,et al. Evaluating functional network inference using simulations of complex biological systems , 2002, ISMB.
[3] Elisa Giovannetti,et al. Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2005, Molecular Pharmacology.
[4] I. Rusyn,et al. Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry , 2008, Metabolomics.
[5] Thomas J. Fuchs,et al. A high-throughput metabolomics method to predict high concentration cytotoxicity of drugs from low concentration profiles , 2011, Metabolomics.
[6] M. Stephens,et al. Scalable Variational Inference for Bayesian Variable Selection in Regression, and Its Accuracy in Genetic Association Studies , 2012 .
[7] D. Hedley,et al. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. , 2000, Cancer research.
[8] Paola Lecca,et al. Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics , 2012, BMC Systems Biology.
[9] Jung-Hsien Chiang,et al. An integrative approach to identifying cancer chemoresistance-associated pathways , 2011, BMC Medical Genomics.
[10] D. Gillespie. A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions , 1976 .
[11] Pasi Soininen,et al. Quantitative high-throughput metabolomics: a new era in epidemiology and genetics , 2012, Genome Medicine.
[12] M. Opper,et al. Chapter 1 Approximate inference for continuous-time Markov processes , 2009 .
[13] I. Voutsadakis. Molecular predictors of gemcitabine response in pancreatic cancer. , 2011, World journal of gastrointestinal oncology.
[14] Godefridus J Peters,et al. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions , 2009, Scandinavian journal of gastroenterology.
[15] C. Ball,et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.
[16] A. Mazo,et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] E. Giovannetti,et al. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer , 2010, The Pharmacogenomics Journal.
[18] Minoru Tada,et al. Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. , 2005, Oncology reports.
[19] Thomas G. Dietterich. What is machine learning? , 2020, Archives of Disease in Childhood.
[20] V. Heinemann,et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.
[21] T. Noda,et al. Identifying Molecular Markers for Chemosensitivity to Gemcitabine in Pancreatic Cancer: Increased Expression of Interferon-Stimulated Gene 15 kd Is Associated With Intrinsic Chemoresistance , 2010, Pancreas.
[22] Manfred Opper,et al. Approximate Inference for Stochastic Reaction processes , 2010, Learning and Inference in Computational Systems Biology.
[23] Jos H. Beijnen,et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine , 2008, Molecular Cancer Therapeutics.
[24] John R. Mackey,et al. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions , 2010, Cancers.
[25] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[26] Tetsuo Arakawa,et al. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer , 2009, Journal of experimental & clinical cancer research : CR.
[27] R. Weinshilboum,et al. Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.
[28] Ben van Ommen,et al. Transcriptomic Coordination in the Human Metabolic Network Reveals Links between n-3 Fat Intake, Adipose Tissue Gene Expression and Metabolic Health , 2011, PLoS Comput. Biol..
[29] T. Okumura,et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007, British Journal of Cancer.
[30] Liang Zhiyong,et al. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines , 2009, Molecular Cancer.
[31] G. Gallick,et al. Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players , 2008, Clinical Cancer Research.
[32] Darren J. Wilkinson. Stochastic Modelling for Systems Biology , 2006 .
[33] Takashi Kimura,et al. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma , 2011, Journal of hepato-biliary-pancreatic sciences.
[34] E. Mini,et al. Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] A. Hajri,et al. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. , 2009, Neoplasia.
[36] Paola Lecca,et al. Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy , 2012, PloS one.
[37] Corrado Priami,et al. Algorithmic systems biology , 2009, CACM.